Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

Notably, this statistic does not include deaths attributed to tuberculosis or the coronavirus disease 2019 (COVID ... processes within the lower respiratory tract. Nonvolatile organic compounds ...

Bovine respiratory disease isn’t going away, but there are things ranchers and farmers can do to reduce disease prevalence.

GSK (NYSE:GSK) continued losses for a seventh straight session as the stock closed 0.61% lower, at $37.51 on Friday.  The ...

Antibodies from the Abrysvo vaccine will be passed from the mothers to the babies. Read more at straitstimes.com.

such as lower respiratory tract disease (LRTD) and pneumonia in older adults. i The RSV vaccine has been approved for older adults aged 60 and above in the country. This adjuvanted vaccine can ...